terraplasma emission control GmbH
terraplasma emission control GmbH is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at terraplasma emission control GmbH.
terraplasma emission control GmbH is a company.
Key people at terraplasma emission control GmbH.
Key people at terraplasma emission control GmbH.
terraplasma GmbH is a deep-tech startup and spin-off of the Max Planck Society, founded in 2011 and based in Garching near Munich, Germany. The company pioneers cold atmospheric plasma (CAP) technology—a partially ionized gas generated from ambient air and electrical energy that inactivates bacteria, fungi, viruses, spores, allergens, and odor molecules without chemicals, heat, UV, or radiation.[1][2][4] It develops and commercializes CAP solutions for medical technology, hygiene, water treatment, odor management, air purification, cosmetics, surface modification, and more, partnering with industry leaders and holding over 60 patents worldwide.[1][5]
terraplasma serves healthcare providers, consumer skincare markets, industrial hygiene sectors, and water management industries, addressing antimicrobial resistance, chemical-free disinfection, and sustainable treatment challenges. Key products include the CE-certified plasma care® for wound healing (via subsidiary terraplasma medical GmbH, founded 2016), consumer devices like Phlas for skin regeneration, and solutions for disinfection, sterilization, and water purification; over 35,000 units have been sold through partners.[3][4][5] Growth is driven by a young, creative team advancing from research prototypes to market-ready innovations across five product lines.[1][4]
terraplasma GmbH emerged from over three decades of cold plasma research at the Max Planck Institute for Extraterrestrial Physics, led by Prof. Dr. Dr. h.c. Gregor Morfill, including experiments on plasma crystallization aboard the International Space Station (ISS).[3][4][5] In 2011, Morfill and Dr. Zimmermann founded the company as a female-founded spin-off of the Max Planck Society to commercialize these findings, starting with the first clinical trial for a compact, affordable plasma device.[1][5]
Early traction came from transferring space-derived plasma physics into practical applications, such as medical wound treatment. This led to the 2016 launch of subsidiary terraplasma medical GmbH, which developed plasma care® for chronic wounds and multi-resistant pathogens.[3] Pivotal moments include launching five products over the past decade and expanding into skincare (e.g., Phlas with hyped about science GmbH) and water treatment, building on extensive R&D know-how.[4][5]
terraplasma rides the antimicrobial resistance (AMR) crisis and sustainability trends, where CAP offers chemical-free alternatives to failing disinfectants like chlorine or antibiotics amid rising superbugs and water scarcity.[1][3][5] Timing aligns with post-pandemic hygiene demands, EU green tech mandates, and space tech commercialization (e.g., ISS plasma insights repurposed for Earth challenges).[3][4]
Market forces favor it: global CAP market growth in medtech (wound care), water purification (vs. energy-intensive reverse osmosis), and consumer health; regulatory wins like CE certification boost adoption.[3][5] terraplasma influences the ecosystem by pioneering CAP standards, partnering across sectors, and enabling scalable, residue-free solutions—positioning cold plasma as a deep-tech disruptor in cleantech and biotech.[1][2][6]
terraplasma is poised to scale water treatment applications, revolutionizing sustainable disinfection by targeting bacteria/viruses/pollutants without chemicals—potentially capturing share in a $100B+ global market amid climate-driven water challenges.[5] Trends like AMR escalation, green regulations, and AI-optimized plasma tech will accelerate growth, with expansions into food safety and industrial hygiene.
Its Max Planck heritage and patent moat ensure enduring influence, evolving from medtech niche to broad cleantech leader—exemplifying how space research fuels tomorrow's antimicrobial innovations, much like its origins transformed ISS experiments into healing tools.[3][4]
